Cancer treatment and research communicationsHumansPancreatic NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsMaleFemale
Oxaliplatin and/or gemcitabine vs. FOLFIRINOX in first-line Advanced pancreatic adenocarcinoma: Real-world efficacy and safety data of moroccan patients.
Hassan Abdelilah Tafenzi, Youssef Ait Takniouine, Ismail Essadi, Rhizlane Belbaraka
Published: 202510.1016/j.ctarc.2025.101036
Abstract
BACKGROUND: While fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) offers a survival advantage in advanced pancreatic adenocarcinoma (PAC) compared to gemcitabine, gemcitabine-oxaliplatin, and gemcitabine-nab-paclitaxel, the outcome…
Preview only. Read the full abstract at the source